New drug aims to get heart surgery patients home sooner
NCT ID NCT07357675
Summary
This trial is testing a new drug called EA-230 to see if it helps people recover faster after heart bypass surgery. The goal is to shorten the time patients need to stay in the hospital and intensive care unit (ICU) and reduce serious complications. About 300 adults scheduled for planned bypass surgery will be randomly assigned to receive either EA-230 or a placebo (inactive substance) during their operation, and neither they nor their doctors will know which one they get.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CORONARY ARTERY DISEASE (CAD) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MAYO clinic
Rochester, Minnesota, 55905, United States
-
Medisch Spectrum Twente
Enschede, Netherlands
-
RadboudUMC
Nijmegen, Netherlands
-
St Thomas' Hospital
London, United Kingdom
-
UZ Gent
Ghent, Belgium
Conditions
Explore the condition pages connected to this study.